XML 65 R51.htm IDEA: XBRL DOCUMENT v3.20.2
Acquisitions (Details) - USD ($)
12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Recognized amounts of identifiable assets acquired, and liabilities assumed    
Goodwill $ 28,090,407 $ 0
Cerecor, Inc.    
Consideration    
Cash and cash equivalents 4,500,000  
Total consideration transferred 10,059,914  
Recognized amounts of identifiable assets acquired, and liabilities assumed    
Inventory, net 459,123  
Prepaid expenses and other current assets 1,743,555  
Other current assets 2,525,886  
Intangible assets 22,700,000  
Accrued product program liabilities (6,683,932)  
Assumed fixed payment obligations (29,837,853)  
Total identifiable net assets (9,393,221)  
Goodwill $ 19,453,135 15,387,064
Cerecor, Inc. | Series G Convertible Preferred Stock    
Consideration    
Shares issued 9,805,845  
Estimated fair value per share of Aytu common stock $ 0.567  
Estimated fair value of equity consideration transferred $ 5,559,914  
Innovus Pharmaceuticals    
Consideration    
Fair value of former Innovus warrants 15,315  
Fair value of contingent value rights 7,049,079  
Forgiveness of note payable owed to the Company 1,350,000  
Total consideration transferred 12,805,263  
Recognized amounts of identifiable assets acquired, and liabilities assumed    
Cash and cash equivalents 390,916  
Accounts receivables, net 278,826  
Inventory, net 1,149,625  
Prepaid expenses and other current assets 1,692,133  
Other long-term assets 36,781  
Right-to-use assets 328,410  
Property, plant and equipment 190,393  
Intangible assets 11,744,000  
Accounts payable and accrued other expenses (7,202,309)  
Other current liabilities (629,601)  
Notes payable (3,056,361)  
Lease liability (754,822)  
Total identifiable net assets 4,167,991  
Goodwill $ 8,637,272 $ 8,374,269
Innovus Pharmaceuticals | Aytu Common Stock    
Consideration    
Shares issued 3,810,393  
Estimated fair value per share of Aytu common stock $ 0.756  
Estimated fair value of equity consideration transferred $ 2,880,581  
Innovus Pharmaceuticals | Series H Convertible Preferred Stock    
Consideration    
Shares issued 1,997,736  
Estimated fair value per share of Aytu common stock $ 0.756  
Estimated fair value of equity consideration transferred $ 1,510,288